Oncimmune Holdings PLC Consortium of Liver Cancer Industry Leaders

TIDMONC

Oncimmune Holdings PLC

23 January 2020

23 January 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Oncimmune included in Consortium of Liver Cancer Industry Leaders to Research Early Detection

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, today announces that it has been included in a consortium of industry leaders, brought together by the Oxford Centre for Early Cancer Detection (OxCODE), to aid in the research of earlier detection of hepatocellular carcinoma.

The programme aims to understand more about changes in the liver as hepatocellular carcinoma develops in order to use this information to inform new and more sensitive diagnostic tests that could detect liver cancer earlier.

The Chief Investigator of the programme, Professor Ellie Barnes has been awarded a Cancer Research UK (CRUK) Early Detection Programme Award that provides funding of GBP2.5 million over the next five years to support the programme.

Alongside a multidisciplinary team involving multiple Oxford researchers, the consortium also includes researchers from Nottingham University, Newcastle University, Glasgow Caledonian University, the University of Bristol, the London School of Hygiene and Tropical Medicine and Aarhus University (Denmark), and industry partners including Oncimmune, Roche Diagnostics, Perspectum Diagnostics, and IPDx; and charity partners the British Liver Trust and the Hepatitis C Trust.

Dr Adam M Hill, Chief Executive Officer of Oncimmune, commented:

"Our participation in this consortium further demonstrates our success of being recognised as a world leading immunodiagnostic group focused on earlier cancer detection. Through this programme and our expertise, better techniques will be developed and executed in order to diagnose liver cancer at an earlier stage giving patients a greater chance of survival."

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Daniel Harris, Victoria Ayton

[phone]

finnCap (Joint Broker)

Geoff Nash, Matthew Radley, Tim Redfern

[phone]

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

[phone]

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

[e-mail]

[phone]

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical multinationals in both autoimmune disease and immuno-oncology. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT(R) Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

What is EarlyCDT Lung?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRASEMFEDESSEEF

(END) Dow Jones Newswires

January 23, 2020 07:30 ET (12:30 GMT)